Ramsay Health Care forecasts double-digit profit growth – is the stock a buy?

The private hospital operator continues to outperform.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Private hospital operator Ramsay Health Care (ASX: RHC), which owns and manages hospitals and day surgeries across Australia, the UK, France and Indonesia has held its Annual General Meeting today at which it reaffirmed its guidance for double-digit growth in profits.

With 121 hospitals in five countries that in total admit around 1.3 million patients per year, Ramsay is a large player in the private hospital space. The firm recorded revenue growth of 5.5% to $4.2 billion and 15.1% growth in core net profit after tax (NPAT) to $291 million in financial year (FY) 2013.

On a per share basis, core earnings per share increased 17.1% to 135.9 cents per share and the dividend was raised 17.4% to 70.5 cps.

Ramsay's impressive growth profile has helped its share price rocket nearly 58% higher in the past year; in comparison the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO) is up 22% over the same period. This has resulted in the stock currently trading on a trailing price-to-core earnings ratio of 27.7 times. This is a hefty multiple and is only justified if the outlook is for particularly strong earnings growth in future years. As such Ramsay's earnings guidance needs to be watched closely.

Contained in the company's outlook statement was confirmation that guidance for core NPAT and core EPS growth of between 12% and 14% in the FY 2014 was still expected to be achieved with "strong industry fundamentals and continuing implementation" of Ramsay's successful growth strategy continuing into the current year.

The question now for shareholders and investors is whether Ramsay's share price has run ahead of its valuation. Its outlook statement combined with its current PE multiple would appear to suggest it has.

Compared with its peer group of multinational health sector stocks, Ramsay's high pricing isn't alone. Plasma products manufacturer CSL (ASX: CSL) trades on a PE of roughly 28 times and is expecting NPAT to grow at approximately 10% this financial year. Meanwhile Sonic Healthcare (ASX: SHL) which provides medical diagnostic services is currently trading on a PE multiple of 19 times and has provided guidance for growth in earnings before interest, tax, depreciation and amortisation of 5% holding currency constant.

Foolish takeaway

A trap for investors is that with the market having moved to multi-year highs, it can blur what is a reasonable price to pay for an investment. One way for investors to avoid this potential pitfall is to focus on historical long-term averages which can help provide a context in which to compare the current market.

Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »